Kodiak Sciences (STU:K27) OCF Yield %: -6.32 (As of Jun. 25, 2026)


STU:K27 Kodiak Sciences Inc STU:K27
27 GF Score
Price €31.62
! 3 Warning Signs
View Full Analysis

What is Kodiak Sciences OCF Yield %?

Kodiak Sciences STU:K27 -2.92% 27 OCF Yield % is -6.32 as of Jun. 25, 2026. GuruFocus rates STU:K27 with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,419 Biotechnology companies, Kodiak Sciences ranks better than 54.76% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Kodiak Sciences's Trailing 12-Month Cash Flow from Operations is €-126.31 Mil, and Market Cap is €1,979.84 Mil. Therefore, Kodiak Sciences's OCF Yield % for today is -6.32%.

The historical rank and industry rank for Kodiak Sciences's OCF Yield % or its related term are showing as below:

STU:K27' s OCF Yield % Range Over the Past 10 Years
Min: -6.32   Med: 0   Max: -6.32
Current: -6.32


During the past 10 years, the highest OCF Yield % of Kodiak Sciences was -6.32%. The lowest was -6.32%. And the median was %.

STU:K27's OCF Yield % is ranked better than
54.76% of 1419 companies
in the Biotechnology industry
Industry Median: -8.46 vs STU:K27: -6.32

Kodiak Sciences's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Kodiak Sciences OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Kodiak Sciences OCF Yield % Related Terms


Kodiak Sciences OCF Yield % Historical Data

* Premium members only.

The historical data trend for Kodiak Sciences's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kodiak Sciences OCF Yield % Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -58.65 -93.33 -21.95 -7.81

Kodiak Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -79.23 -72.82 -15.93 -9.05 -7.65

STU:K27 vs RARE, NKTR, ELVN: OCF Yield % Comparison

For the Biotechnology subindustry, Kodiak Sciences's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kodiak Sciences OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kodiak Sciences's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Kodiak Sciences's OCF Yield % falls into.


STU:K27
27GF Score
Kodiak Sciences Inc STU:K27
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kodiak Sciences OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Kodiak Sciences's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-116.151 / 1487.13264
=-7.81%

Kodiak Sciences's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-34.608 * 4 / 1808.7396
=-7.65%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -6.32 mean?
Kodiak Sciences (STU:K27) has a OCF Yield % of -6.32 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Kodiak Sciences and its competitors. According to the industry distribution chart, Kodiak Sciences ranks #642 out of 1419 companies in the Biotechnology industry, placing it in the top 45.2%.
Is Kodiak Sciences' OCF Yield % too high?
Kodiak Sciences' current OCF Yield % is -6.32. Based on the distribution chart, Kodiak Sciences ranks #642 out of 1419 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kodiak Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' OCF Yield % compare to RARE and NKTR?
According to the Biotechnology industry distribution chart, Kodiak Sciences ranks #642 out of 1419 companies for OCF Yield %. This puts Kodiak Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Kodiak Sciences and its competitors. Kodiak Sciences's current OCF Yield % is -6.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (STU:K27) has a current OCF Yield % of -6.32. The current OCF Yield % is -6.32. Kodiak Sciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Kodiak Sciences (STU:K27), the current OCF Yield % is -6.32 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kodiak Sciences Business Description

Other Exchanges KOD:USA
Address 1250 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
27GF Score

Get the complete analysis for STU:K27

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.62
Price